On 2026-09-15, Barclays raised its MSTR price target to $160 from $125 (+28.0%).
Barclays 于 2026-09-15 将 MSTR 目标价上调至 $160，此前为 $125，变动幅度 +28.0%。
For information only. Not investment advice.内容仅供参考，不构成投资建议。
MSTR options: estimated premium turnover $6M; largest line MSTR261009C00141000 (Call) $248.0K (expires 2026-10-09)MSTR 期权异动：所扫描合约成交权利金估算约 $6M；最大合约 MSTR261009C00141000（看涨期权 Call）约 $248.0K（2026-10-09 到期）
Options Activity · September 18, 2026期权异动 · 2026/9/18
MSTR regulated product launch: RMTG's ISSCA Division Launches Integrative Fellowship in Point-of-Care Regenerative Medicine through ISSCA AI(TM) StrategyStrategy Inc（MSTR）正式推出获批药品或治疗产品
Material Company Event · September 17, 2026公司公告 · 2026/9/17
Alliance Global initiates coverage of MSTR with BuyAlliance Global 首次覆盖 微策略 (MSTR)，初始评级 Buy
Rating Change · September 1, 2026评级变动 · 2026/9/1
